MX2024005647A - Tratamiento de trastornos hepaticos con un agonista del thr-\03b2. - Google Patents

Tratamiento de trastornos hepaticos con un agonista del thr-\03b2.

Info

Publication number
MX2024005647A
MX2024005647A MX2024005647A MX2024005647A MX2024005647A MX 2024005647 A MX2024005647 A MX 2024005647A MX 2024005647 A MX2024005647 A MX 2024005647A MX 2024005647 A MX2024005647 A MX 2024005647A MX 2024005647 A MX2024005647 A MX 2024005647A
Authority
MX
Mexico
Prior art keywords
thr
agonist
treatment
liver disorders
disorders
Prior art date
Application number
MX2024005647A
Other languages
English (en)
Spanish (es)
Inventor
Feng Jin
Kevin Klucher
Christopher T Jones
Erin K Quirk
Matt Duan
Jianwei Bian
Sheng Guo
D Barry Crittenden
Qianqian Dong
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of MX2024005647A publication Critical patent/MX2024005647A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
MX2024005647A 2021-11-11 2022-11-11 Tratamiento de trastornos hepaticos con un agonista del thr-\03b2. MX2024005647A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021130083 2021-11-11
CN2022097426 2022-06-07
PCT/CN2022/131297 WO2023083288A1 (en) 2021-11-11 2022-11-11 TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST

Publications (1)

Publication Number Publication Date
MX2024005647A true MX2024005647A (es) 2024-05-24

Family

ID=86335128

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005647A MX2024005647A (es) 2021-11-11 2022-11-11 Tratamiento de trastornos hepaticos con un agonista del thr-\03b2.

Country Status (14)

Country Link
US (1) US20240293416A1 (cg-RX-API-DMAC7.html)
EP (1) EP4429666A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024544538A (cg-RX-API-DMAC7.html)
KR (1) KR20240101642A (cg-RX-API-DMAC7.html)
CN (1) CN118871113A (cg-RX-API-DMAC7.html)
AU (1) AU2022388507A1 (cg-RX-API-DMAC7.html)
CA (1) CA3238108A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001399A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024007225A2 (cg-RX-API-DMAC7.html)
IL (1) IL312637A (cg-RX-API-DMAC7.html)
MX (1) MX2024005647A (cg-RX-API-DMAC7.html)
PE (1) PE20241327A1 (cg-RX-API-DMAC7.html)
TW (1) TW202332447A (cg-RX-API-DMAC7.html)
WO (1) WO2023083288A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
WO2025245216A1 (en) * 2024-05-22 2025-11-27 Terns Pharmaceuticals, Inc. Treatment of liver disorders with a thr-beta agonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX394463B (es) * 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
TW202615431A (zh) * 2018-07-02 2026-04-16 美商瑪德瑞高製藥公司 2-(3,5-二氯-4-((5-異丙基-6-側氧基-1,6-二氫噠嗪-3-基)氧)苯基)-3,5-二側氧基-2,3,4,5-四氫-1,2,4-三嗪-6-腈之固體型式
CN121081472A (zh) * 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
WO2020228577A1 (zh) * 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
WO2021121210A1 (zh) * 2019-12-16 2021-06-24 江苏恒瑞医药股份有限公司 并环类衍生物、其制备方法及其在医药上的应用
WO2021231646A1 (en) * 2020-05-13 2021-11-18 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
CN114437034A (zh) * 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法

Also Published As

Publication number Publication date
CL2024001399A1 (es) 2024-11-08
CN118871113A (zh) 2024-10-29
TW202332447A (zh) 2023-08-16
WO2023083288A1 (en) 2023-05-19
CA3238108A1 (en) 2023-05-19
EP4429666A1 (en) 2024-09-18
PE20241327A1 (es) 2024-06-26
AU2022388507A1 (en) 2024-06-20
KR20240101642A (ko) 2024-07-02
JP2024544538A (ja) 2024-12-03
IL312637A (en) 2024-07-01
US20240293416A1 (en) 2024-09-05
EP4429666A4 (en) 2025-12-24
CO2024007225A2 (es) 2024-10-31

Similar Documents

Publication Publication Date Title
MX2022014238A (es) Tratamiento combinado de trastornos hepáticos.
MX2022014237A (es) Tratamiento combinado de trastornos hepáticos.
MX2024006123A (es) Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo.
ZA202300875B (en) Kat6 inhibitor methods and combinations for cancer treatment
ZA202204929B (en) Rimegepant for cgrp related disorders
MX2021002305A (es) Tratamiento de trastornos del higado.
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
MX2011007397A (es) Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos.
GB2503852A (en) Compounds for the treatment of neuropsychiatric disorders
PH12013502487A1 (en) Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
CO2024007225A2 (es) Tratamiento de trastornos hepáticos con un agonista del thr-β
GB2475660A (en) Methods and kits for treating cluster headache disorders
EA201890968A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
ZA202304965B (en) Combination therapy for treating cancer
TW200806325A (en) Therapeutic uses of inhibitors of RTP801
MX2010002667A (es) Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
PH12023552792A1 (en) Combination therapies for the treatment of cancer
MX2023003993A (es) Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina.
MX2022004524A (es) Tratamiento génico para la enfermedad de alzheimer.
MX2023002332A (es) Terapia con antagonistas del gen 3 de activacion de linfocitos (lag-3) para carcinoma hepatocelular.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2025000673A (es) Metodos de administracion de nalbufina
MX2022005407A (es) Tratamiento de trastornos hepaticos.
MX2024009649A (es) Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.